Bibliometric analysis of research trends on 0.05% cyclosporine A based on Web of Science

Objective  To systematically analyze the current research landscape and development trends of 0.05% cyclosporine A (CsA) in the field of ocular surface diseases using bibliometric methods.

Methods  Relevant literature on 0.05% CsA published between January 2000 and September 2024 was retrieved from the Web of Science Core Collection.A total of 244 articles that met the inclusion criteria were analyzed using the bibliometric visualization tool CiteSpace.The analysis included publication volume, core authors, research institutions and country distribution, keyword co-occurrence, burst detection, clustering, and co-citation patterns.

Results  From January 2000 to September 2024, the overall number of publications showed a fluctuating upward trend, peaking in 2022.A total of 513 authors were identified, with Yoon Kyung Chul contributing the most publications.The research involved 331 institutions, with Chonnam National University and Harvard University showing outstanding performance.A total of 39 countries were involved, with the United States leading in publication volume (93 articles) and demonstrating high centrality and collaboration strength.China ranked fifth with 19 articles and has shown rapid growth in recent years.Keyword co-occurrence analysis revealed that the most central research themes were dry eye disease and 0.05% CsA.Other hotspots included allergic conjunctivitis, meibomian gland dysfunction, Sjögren syndrome, and postoperative dry eye management.Clustering and timeline analyses indicated that research directions have expanded from basic therapy to novel formulations, combination treatments, and personalized approaches.Co-citation analysis showed that highly cited references had a significant influence om the field.Highly cited publications from the past three years reflected a sustained focus on novel formulations and long-term efficacy evaluation.

Conclusions  0.05% CsA plays a crucial role in the treatment of various ocular surface diseases.Future research should focus on developing novel formulations, combination therapy strategies, and conducting large-scale, long-term clinical trials to optimize treatment outcomes and advance the field.

KEYWORDS：